Therapy Detail

Therapy Name Pembrolizumab
Synonym
Therapy Description

Keytruda (pembrolizumab) is an antibody against PD-1, resulting in activation of T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved for use in patients with melanoma, head and neck squamous cell carcinoma, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, MSI-H or dMMR solid tumors, PD-L1 expressing NSCLC, gastric cancer, GEJ adenocarcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, in combination with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, and in combination with axitinib for renal cell carcinoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Pembrolizumab Keytruda MK-3475 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 50 Keytruda (pembrolizumab) is an antibody against PD-1, resulting in activation of T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved for use in patients with melanoma, head and neck squamous cell carcinoma, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, MSI-H or dMMR solid tumors, PD-L1 expressing NSCLC, gastric cancer, GEJ adenocarcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, in combination with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, and in combination with axitinib for renal cell carcinoma (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown fibrous histiocytoma not applicable Pembrolizumab Phase II Actionable In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in complete response in 10% (1/10) and partial response in 30% (3/10) of patients with undifferentiated pleomorphic sarcoma (malignant fibrous histiocytoma) (J Clin Oncol 35, 2017 (suppl; abstr 11008)). detail...
KRAS mutant TP53 mutant non-small cell lung carcinoma predicted - sensitive Pembrolizumab Phase I Actionable In a clinical study, a retrospective analysis of a Phase I trial demonstrated four non-small cell lung carcinoma (NSCLC) patients co-harboring a TP53 mutation and KRAS mutation had greater progression free survival compared to NSCLC patients harboring a single TP53 mutation or single KRAS mutation when treated with Keytruda (pembrolizumab) (PMID: 28039262). 28039262
Unknown unknown primary mediastinal B-cell lymphoma not applicable Pembrolizumab FDA approved Actionable In a Phase II trial (KEYNOTE-170) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 45% (24/53) in patients with primary mediastinal large B-cell lymphoma, with a complete response rate of 13% (7/53), and a median progression-free survival of 5.5 months (ASH Annual Meeting Dec 2018, Session 626, abstract 228; NCT02576990). detail... detail...
Unknown unknown lung small cell carcinoma not applicable Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for small cell lung cancer patients who have relapsed after primary therapy (NCCN.org). detail...
Unknown unknown liposarcoma not applicable Pembrolizumab Phase II Actionable In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in partial response in 20% (2/10) of patients with dedifferentiated liposarcoma (J Clin Oncol 35, 2017 (suppl; abstr 11008)). detail...
BRAF mutant IDH1 wild-type glioblastoma multiforme predicted - sensitive Pembrolizumab Clinical Study - Cohort Actionable In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119). 30742119
Unknown unknown melanoma not applicable Pembrolizumab FDA approved Actionable In a Phase III trial (KEYNOTE-006) that supported FDA approval, treatment with Keytruda (pembrolizumab) resulted in improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic melanoma, with a 6-month PFS rate of 47.3% for the every 2 week schedule and 46.4% for the every 3 week schedule versus 26.5% with Yervoy (ipilimumab) (PMID: 25891173; NCT01866319). 25891173
Unknown unknown melanoma not applicable Pembrolizumab FDA approved Actionable In a Phase II trial (KEYNOTE-002) that supported FDA approval, treatment with Keytruda (pembrolizumab) resulted in improved progression-free survival (PFS) compared to chemotherapy in patients with Yervoy (ipilimumab)-refractory melanoma, with a HR of 0.57 (p<0.0001) in the 2mg/kg group and a HR of 0.50 (p<0.0001) in the 10mg/kg group (PMID: 26115796; NCT01704287). 26115796
Unknown unknown melanoma not applicable Pembrolizumab FDA approved Actionable In a Phase III trial (KEYNOTE-054) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in significantly improved recurrence-free survival rate at 1 year (75.4% vs 61.0%, HR=0.57, p<0.001) compared to placebo in patients with resected, high-risk stage III melanoma (PMID: 29658430; NCT02362594). 29658430
Unknown unknown leiomyosarcoma no benefit Pembrolizumab Phase II Actionable In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 0% (0/10) in patients with leiomyosarcoma (J Clin Oncol 35, 2017 (suppl; abstr 11008)). detail...
Unknown unknown biliary tract cancer not applicable Pembrolizumab Phase II Actionable In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) demonstrated efficacy in patients with advanced biliary tract cancer regardless of CD274 (PD-L1) status, resulted in partial response in 5.8% (6/104) and stable disease in 16% (17/104) of patients; objective response rate, median progression-free survival, and median overall survival were 6.6%, 1.9, and 7.2 months in patients with CPS?1 (n?=?61), and 2.9%, 2.1, and 9.6 months in patients with CPS<1 (n?=?34) (Ann Oncol 29(suppl_8); NCT02628067). detail...
Unknown unknown head and neck squamous cell carcinoma not applicable Pembrolizumab FDA approved Actionable In a Phase Ib trial (KEYNOTE-012) that supported FDA approval, treatment with Keytruda (pembrolizumab) resulted in an objective response rate of 18% (24/132; 4 complete response, 20 partial response) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (PMID: 27247226; NCT01848834). detail... 27247226
BRAF mut PTEN loss melanoma no benefit Pembrolizumab Preclinical Actionable In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196). 26645196
IDH1 wild-type PTPN11 mutant glioblastoma multiforme predicted - sensitive Pembrolizumab Clinical Study - Cohort Actionable In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119). 30742119
Unknown unknown hepatocellular carcinoma not applicable Pembrolizumab FDA approved Actionable In a Phase II trial (KEYNOTE-224) that suported FDA approval, Keytruda (pembrolizumab) treatment resulted in an overall response rate of 16.3% (17/104, 1 complete response, 16 partial response), and stable disease in 45.2% (47/104) of hepatocellular carcinoma patients previously treated with sorafenib, with a median progression-free survival of 4.8 months (J Clin Oncol, 36 (4_suppl), February 2018, 209-209; NCT02702414). detail...
Unknown unknown Hodgkin's lymphoma not applicable Pembrolizumab FDA approved Actionable In a Phase II trial (KEYNOTE-087) that supported FDA approval, Keytrude (pembrolizumab) treatment resulted in an overall response rate of 69% (145/210) in patients with relapsed or refractory classical Hodgkin lymphoma (PMID: 28441111; NCT02453594). 28441111
Unknown unknown chondrosarcoma not applicable Pembrolizumab Phase II Actionable In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in partial response in 20% (1/5) of patients with chondrosarcoma (J Clin Oncol 35, 2017 (suppl; abstr 11008)). detail...
MET exon 14 non-small cell lung carcinoma unknown Pembrolizumab Clinical Study Actionable In a retrospective study, treatment with single agent PD-1/PD-L1 checkpoint inhibitors (Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), or combined Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a 17% (4/24) overall response rate, and a 1.9-month median progression-free survival in patients with lung cancer harboring alterations in MET exon 14, and responses were not associated with PD-L1 expression or tumor mutational burden (PMID: 30165371). 30165371
BRAF V600E melanoma decreased response Pembrolizumab Clinical Study Actionable In a retrospective analysis, patients with melanoma harboring BRAF V600E (n=84) had decreased response rates (29% vs. 53%, p=0.059), progression-free survival (2.7 vs. 19 months, p=0.049), and overall survival (11.7 vs. 20.4 months, p=0.081) relative to patients with BRAF V600K (n=19) when treated with Keytruda (pembrolizumab) (n=62 and 17 for BRAF V600E and V600K, respectively) or Opdivo (nivolumab) (n=22 and 2 for BRAF V600E and V600K, respectively) (PMID: 30630828). 30630828
KRAS mutant non-small cell lung carcinoma predicted - sensitive Pembrolizumab Phase I Actionable In a clinical study, a retrospective analysis of a Phase I trial demonstrated non-small cell lung carcinoma (NSCLC) patients harboring either a TP53 mutation (n=15) or KRAS mutation (n=8) had greater progression free survival compared to NSCLC patients harboring wild-type TP53 or KRAS (n=15) (14.5mo vs 14.7mo vs 3.5mo, respectively) when treated with Keytruda (pembrolizumab) (PMID: 28039262). 28039262
KRAS mutant non-small cell lung carcinoma predicted - sensitive Pembrolizumab Clinical Study - Meta-analysis Actionable In a meta-analysis, compared to Taxotere (docetaxel), treatment with check point inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in KRAS mutant (HR=0.65, P=0.03) but not KRAS wild-type (HR=0.86, P=0.24) non-small cell lung carcinoma patients (PMID: 29270615). 29270615
IDH1 wild-type PTEN mutant glioblastoma multiforme resistant Pembrolizumab Clinical Study - Cohort Actionable In a retrospective analysis, PTEN mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who did not respond to anti-PD-1 therapy, with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who responded (odds ratio=0.85, p=0.0063), with 23 PTEN mutations identified in 32 non-responders and 3 in 13 responders (PMID: 30742119). 30742119
Unknown unknown transitional cell carcinoma not applicable Pembrolizumab FDA approved Actionable In a Phase III (KEYNOTE-045) trial that supported FDA approval, treatment with Keytruda (pembrolizumab) resulted in an improved median overall survival of 10.3 months, compared to 7.4 months with chemotherapy (p=0.002), and an objective response rate of 21.1% vs. 11.4% in the chemotherapy group in patients with platinum-refractory advanced urothelial carcinoma (PMID: 28212060; NCT02256436). 28212060
JAK2 inact mut melanoma predicted - resistant Pembrolizumab Case Reports/Case Series Actionable In a clinical study, a melanoma patient treated with Keytruda (pembrolizumab) initially demonstrated a partial response, however, post 734 days developed disease progression due to a splice site mutation in JAK2, which resulted in an intron inclusion and an early stop codon, leading to a loss of protein expression (PMID: 27433843). 27433843
Unknown unknown neuroendocrine tumor not applicable Pembrolizumab Phase II Actionable In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in partial response in 3.7% (4/107, 3 pancreatic, 1 GI) and stable disease in 57.0% (61/107) of patients with heavily pretreated neuroendocrine tumors, all 4 responders were CD274 (PD-L1)-negative (Journal of Clinical Oncology 37, no. 4_suppl (February 1 2019) 190-190; NCT02628067). detail...
PTEN positive melanoma sensitive Pembrolizumab Clinical Study - Cohort Actionable In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Keytruda (pembrolizumab) (PMID: 26645196). 26645196
Unknown unknown Ewing sarcoma no benefit Pembrolizumab Phase II Actionable In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in no objective response (0/13) in patients with Ewing sarcoma (J Clin Oncol 35, 2017 (suppl; abstr 11008)). detail...
Unknown unknown Merkel cell carcinoma not applicable Pembrolizumab FDA approved Actionable In a Phase II trial (KEYNOTE-017) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in a confirmed objective response rate of 50% (21/42, complete response 19%, partial response 31%) in patients with advanced Merkel cell carcinoma naive to systemic therapy (J Clin Oncol 36, no. 15_suppl (May 20 2018) 9506-9506; NCT02267603). detail...
Unknown unknown osteosarcoma not applicable Pembrolizumab Phase II Actionable In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in partial response in 5% (1/22) of patients with osteosarcoma (J Clin Oncol 35, 2017 (suppl; abstr 11008)). detail...
TP53 mutant non-small cell lung carcinoma predicted - sensitive Pembrolizumab Phase I Actionable In a clinical study, a retrospective analysis of a Phase I trial demonstrated non-small cell lung carcinoma (NSCLC) patients harboring either a TP53 mutation (n=15) or KRAS mutation (n=8) had greater progression free survival compared to NSCLC patients harboring wild-type TP53 or KRAS (n=15) (14.5mo vs 14.7mo vs 3.5mo, respectively) when treated with Keytruda (pembrolizumab) (PMID: 28039262). 28039262
BRAF V600K melanoma predicted - sensitive Pembrolizumab Clinical Study - Cohort Actionable In a retrospective analysis, patients with melanoma harboring BRAF V600K (n=19) had increased tumor mutational burden and greater response rates (53% vs. 29%, p=0.059), progression-free survival (19 vs. 2.7 months, p=0.049), and overall survival (20.4 vs. 11.7 months, p=0.081) relative to patients with BRAF V600E (n=84) when treated with Keytruda (pembrolizumab) (n=17 and 62 for BRAF V600K and V600E, respectively) or Opdivo (nivolumab) (n=2 and 22 for BRAF V600K and V600E, respectively) (PMID: 30630828). 30630828
Unknown unknown sarcoma not applicable Pembrolizumab Phase II Actionable In a Phase II trial, treatment with Keytruda (pembrolizumab) resulted in a progression-free survival (PFS) of 18 weeks and an objective response rate of 18% (7/40) in patients with soft tissue sarcoma, including four with pleomorphic sarcoma, two with liposarcoma, and one with synovial sarcoma, and PFS of 8 weeks and an objective response rate of 5% (2/40) in patients with bone sarcoma, including one with osteosarcoma and one with chondrosarcoma (PMID: 28988646; NCT02301039). detail... 28988646
Unknown unknown bone cancer not applicable Pembrolizumab Phase II Actionable In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in an overall response rate of 5% (2/40) and 12-week progression free rate of 28% (11/40) in patients with bone sarcoma (J Clin Oncol 35, 2017 (suppl; abstr 11008)). detail...
Unknown unknown non-small cell lung carcinoma not applicable Pembrolizumab Clinical Study - Meta-analysis Actionable In a meta-analysis, compared to Taxotere (docetaxel), treatment with check point inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival (HR=0.69, p<0.001) in non-small cell lung carcinoma patients (PMID: 29270615). 29270615
PTEN dec exp melanoma decreased response Pembrolizumab Clinical Study - Cohort Actionable In a clinical study, melanoma patients with PTEN expression in less than 10% of tumor cells demonstrated decreased response to anti-PD-1 antibodies, including Keytruda (pembrolizumab), compared to patients in which PTEN is present in over 10% of tumor cells (PMID: 26645196). 26645196
Unknown unknown synovial sarcoma not applicable Pembrolizumab Phase II Actionable In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in partial response in 10% (1/10) of patients with synovial sarcoma (J Clin Oncol 35, 2017 (suppl; abstr 11008)). detail...
ALK rearrange non-small cell lung carcinoma no benefit Pembrolizumab Clinical Study - Cohort Actionable In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694). 27225694
ALK rearrange non-small cell lung carcinoma no benefit Pembrolizumab Guideline Actionable Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org). detail...
Unknown unknown bladder urothelial carcinoma not applicable Pembrolizumab Phase II Actionable In a Phase II clinical study (PURE-01), 42% (21/50) of patients with muscle invasive bladder cancer treated with neoadjuvant Keytruda (pembrolizumab) had complete pathological responses at disease resection (PMID: 30343614; NCT02736266). 30343614
Clinical Trial Phase Therapies Title Recruitment Status
NCT02546986 Phase II Azacitidine Pembrolizumab Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer Active, not recruiting
NCT03325101 Phase Ib/II Pembrolizumab Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery Recruiting
NCT03007732 Phase II Pembrolizumab + SD-101 Pembrolizumab Pembrolizumab in Combination With Intratumoral SD-101 Therapy Recruiting
NCT02600949 Phase I Pembrolizumab Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma Active, not recruiting
NCT03245489 Phase I Pembrolizumab Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting
NCT02530502 Phase Ib/II Temozolomide Pembrolizumab Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting
NCT03244384 Phase III Pembrolizumab Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer Recruiting
NCT02964559 Phase II Pembrolizumab Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer Recruiting
NCT03695471 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides Recruiting
NCT02658279 Phase I Pembrolizumab Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype Recruiting
NCT02767934 Phase II Pembrolizumab Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia Recruiting
NCT03498612 Phase II Pembrolizumab Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases Recruiting
NCT02642809 Phase I Pembrolizumab Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers Active, not recruiting
NCT02489357 Phase I Degarelix Pembrolizumab Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer Completed
NCT03804944 Phase II CDX-301 CDX-301 + Pembrolizumab Pembrolizumab Converting HR+ Breast Cancer Into an Individualized Vaccine (CBCV) Not yet recruiting
NCT02771197 Phase II Fludarabine + Melphalan Pembrolizumab Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant Recruiting
NCT02359851 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Advanced Uveal Melanoma Active, not recruiting
NCT03765918 Phase III Pembrolizumab Cisplatin + Pembrolizumab Cisplatin Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) Recruiting
NCT02358031 Phase III Cetuximab Pembrolizumab Fluorouracil Carboplatin Cisplatin A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) Active, not recruiting
NCT02408042 Phase Ib/II Rituximab Carboplatin + Etoposide + Ifosfamide Pembrolizumab Brentuximab vedotin Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) Withdrawn
NCT02644369 Phase II Pembrolizumab Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) Active, not recruiting
NCT03833167 Phase III Pembrolizumab Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) Recruiting
NCT03065400 Phase II Pembrolizumab PD-1 Inhibition in Advanced Myeloproliferative Neoplasms Recruiting
NCT03449238 Phase Ib/II Pembrolizumab Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients Recruiting
NCT02637531 Phase I Pembrolizumab IPI-549 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Recruiting
NCT02089685 Phase Ib/II Ipilimumab peginterferon alfa-2b Pembrolizumab Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) Active, not recruiting
NCT03325166 Phase II Pembrolizumab Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases Recruiting
NCT03698019 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery Recruiting
NCT03248570 Phase II Pembrolizumab Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects Recruiting
NCT03988647 Phase II Pembrolizumab Phase II Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma Not yet recruiting
NCT03311672 Phase II Pembrolizumab T-Cell PET Imaging With [18F]F-AraG in Lung Cancer Recruiting
NCT03390504 Phase III Pembrolizumab Erdafitinib Docetaxel + Vinflunine A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations Recruiting
NCT02504372 Phase III Pembrolizumab Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) Recruiting
NCT02576990 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Primary Mediastinal Large B-cell Lymphoma (MK-3475-170/KEYNOTE-170) Active, not recruiting
NCT03056599 Gemcitabine Interferon alpha-2b Doxorubicin Pembrolizumab Eribulin interferon gamma Ipilimumab Trabectedin Aldesleukin Bortezomib Docetaxel Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma Active, not recruiting
NCT03089606 Phase II Pembrolizumab Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker Recruiting
NCT02599779 Phase II Pembrolizumab A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients Recruiting
NCT03419130 Phase II Pembrolizumab Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer Withdrawn
NCT03844750 Phase II Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery Not yet recruiting
NCT03634241 Phase II Pembrolizumab Pembrolizumab in Treating Participants With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules Recruiting
NCT03087760 Phase II Pembrolizumab Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer Recruiting
NCT03432741 Phase I Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Suspended
NCT03631199 Phase III Cisplatin Paclitaxel Nab-paclitaxel Carboplatin Canakinumab + Pembrolizumab Pembrolizumab Pemetrexed Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1) Recruiting
NCT02467361 Phase Ib/II Nivolumab Pembrolizumab Ipilimumab Napabucasin A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers Active, not recruiting
NCT03520686 Phase II Pembrolizumab ALT-803 + Pembrolizumab QUILT-2.023: A Study of ALT-803, a Fusion Protein Activator of Natural Killer and T-Cells, in Combination With Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients With Metastatic NSCLC. Recruiting
NCT02906332 Phase II Pembrolizumab Dexamethasone Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) Active, not recruiting
NCT02494583 Phase III Capecitabine Cisplatin + Fluorouracil Pembrolizumab Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) Active, not recruiting
NCT02331368 Phase II Lenalidomide Melphalan Pembrolizumab Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma Completed
NCT02955758 Phase II Pembrolizumab Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Recruiting
NCT02267603 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer Active, not recruiting
NCT03035331 Phase Ib/II Pembrolizumab Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Recruiting
NCT02362997 Phase II Pembrolizumab Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL Recruiting
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting
NCT02638090 Phase Ib/II Pembrolizumab Vorinostat Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT02559687 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) Active, not recruiting
NCT02728830 Phase I Pembrolizumab A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers Active, not recruiting
NCT02595866 Phase I Pembrolizumab Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Recruiting
NCT02179918 Phase I Utomilumab Pembrolizumab A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) Completed
NCT03898180 Phase III Lenvatinib + Pembrolizumab Pembrolizumab Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) Recruiting
NCT02399371 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Malignant Mesothelioma Active, not recruiting
NCT03793179 Phase III Carboplatin + Pembrolizumab + Pemetrexed Pembrolizumab + Pemetrexed Pembrolizumab Carboplatin + Pemetrexed Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer Recruiting
NCT02335411 Phase II Cisplatin + Fluorouracil + Pembrolizumab Pembrolizumab A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) Active, not recruiting
NCT02255097 Phase II Pembrolizumab Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) Active, not recruiting
NCT02311582 Phase Ib/II Pembrolizumab MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas Recruiting
NCT02853305 Phase III Pembrolizumab Carboplatin + Cisplatin + Gemcitabine Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) Active, not recruiting
NCT03546582 Phase II Pembrolizumab SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE) Recruiting
NCT03237572 Phase I Pembrolizumab Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48) Recruiting
NCT02625961 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) Recruiting
NCT02447003 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) Active, not recruiting
NCT02632344 Phase II Pembrolizumab Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement Active, not recruiting
NCT03331562 Phase II Pembrolizumab Paricalcitol + Pembrolizumab A SU2C Catalyst Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer Recruiting
NCT02787005 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199) Active, not recruiting
NCT02837042 Phase II Pembrolizumab Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Recruiting
NCT02014636 Phase I Pazopanib Pembrolizumab Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC) Completed
NCT02296684 Phase II Pembrolizumab Cisplatin Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma Recruiting
NCT02690948 Phase II Pembrolizumab + Vismodegib Pembrolizumab Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer Completed
NCT02977468 Phase I Pembrolizumab Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT) Recruiting
NCT02557321 Phase Ib/II PV-10 Pembrolizumab PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma Recruiting
NCT02621151 Phase II Pembrolizumab Gemcitabine Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder Recruiting
NCT03366844 Phase I Pembrolizumab Pilot; Open Label; Breast Cancer; Preoperative Pembrolizumab + Radiation Recruiting
NCT02959463 Phase I Pembrolizumab Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma Recruiting
NCT03224871 Phase I Pembrolizumab Aldesleukin Nivolumab A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. Recruiting
NCT03820986 Phase III Lenvatinib + Pembrolizumab Pembrolizumab Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) Recruiting
NCT03568058 Phase I Pembrolizumab Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Recruiting
NCT02318771 Phase I Pembrolizumab Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer Active, not recruiting
NCT02437370 Phase I Pembrolizumab Gemcitabine Docetaxel Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer Recruiting
NCT02453594 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) Active, not recruiting
NCT03290079 Phase II Pembrolizumab Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas Suspended
NCT03210662 Phase II Pembrolizumab Pembrolizumab and Fractionated External Beam Radiotherapy (EBRT) in Patients With Non-Hodgkin Lymphoma (NHL) Recruiting
NCT03732950 Phase II Pembrolizumab Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer Not yet recruiting
NCT02142738 Phase III Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Active, not recruiting
NCT02460198 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) Active, not recruiting
NCT03190213 Phase II Pembrolizumab Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma (Pembro NEC) Terminated
NCT03832569 Phase II Pembrolizumab Study of Pembrolizumab or Placebo Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors Recruiting
NCT02359019 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy Active, not recruiting
NCT02132754 Phase I Pembrolizumab MK-4166 Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001) Active, not recruiting
NCT02362035 Phase Ib/II Acalabrutinib Pembrolizumab ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145) Active, not recruiting
NCT03189186 Phase I Pembrolizumab Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas Withdrawn
NCT03142334 Phase III Pembrolizumab Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) Recruiting
NCT02332668 Phase Ib/II Pembrolizumab A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051) Recruiting
NCT03316573 Phase II Pembrolizumab A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas Recruiting
NCT02611960 Phase II Pembrolizumab Capecitabine + Docetaxel + Gemcitabine Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122) Active, not recruiting
NCT03358472 Phase III Pembrolizumab Carboplatin + Fluorouracil Epacadostat + Pembrolizumab Cetuximab + Cisplatin Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) Active, not recruiting
NCT03286114 Phase I Pembrolizumab Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab Recruiting
NCT03728972 Phase II Pembrolizumab Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type Recruiting
NCT02362594 Phase III Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054) Active, not recruiting
NCT02578680 Phase III Carboplatin Pembrolizumab Pemetrexed Cisplatin Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) Active, not recruiting
NCT02422381 Phase Ib/II Gemcitabine Pembrolizumab MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02483247 Phase Ib/II Paclitaxel Doxorubicin Capecitabine Nivolumab Sunitinib Pembrolizumab BBI503 A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer Active, not recruiting
NCT03072160 Phase II Pembrolizumab Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer Recruiting
NCT03070392 Phase II Dacarbazine Ipilimumab Pembrolizumab IMCgp100 Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma Recruiting
NCT02454179 Phase II Pembrolizumab Acalabrutinib Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma Unknown status
NCT02684292 Phase III Brentuximab vedotin Pembrolizumab Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) Active, not recruiting
NCT02499835 Phase Ib/II Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer Recruiting
NCT02541565 Phase I Pembrolizumab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Rituximab Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma Recruiting
NCT02837263 Phase I Pembrolizumab PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer Recruiting
NCT02364076 Phase II Pembrolizumab MK-3475 in Patients With Thymic Carcinoma Active, not recruiting
NCT03099564 Phase I Pembrolizumab Pembrolizumab Plus Y90 Radioembolization in HCC Subjects Recruiting
NCT02830594 Phase II Pembrolizumab Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer Recruiting
NCT02886585 Phase II Pembrolizumab Pembrolizumab In Central Nervous System Metastases Recruiting
NCT02658097 Phase II Pembrolizumab A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC Recruiting
NCT03932409 Phase I Pembrolizumab Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer (FIERCE) Not yet recruiting
NCT02563002 Phase III Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) Active, not recruiting
NCT03241927 Phase II Pembrolizumab Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT) Terminated
NCT02289209 Phase II Pembrolizumab Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Recruiting
NCT02650999 Phase Ib/II Pembrolizumab Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas Active, not recruiting
NCT02880345 Phase 0 Pembrolizumab RADVAX: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy Withdrawn
NCT03725059 Phase III Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Cyclophosphamide + Epirubicin + Paclitaxel Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) Recruiting
NCT02949219 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Active, not recruiting
NCT02882282 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias Recruiting
NCT03319745 Phase II Pembrolizumab A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy Recruiting
NCT03092323 Phase II Pembrolizumab A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032) Recruiting
NCT02755272 Phase II Pembrolizumab Carboplatin + Gemcitabine A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer Recruiting
NCT02263508 Phase Ib/II Pembrolizumab Talimogene laherparepvec MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma Active, not recruiting
NCT02608385 Phase I Pembrolizumab Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors Recruiting
NCT02303990 Phase I Pembrolizumab RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Active, not recruiting
NCT02853344 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Active, not recruiting
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Recruiting
NCT02511184 Phase I Crizotinib Pembrolizumab Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients Terminated
NCT02451930 Phase I Necitumumab Pembrolizumab A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC Active, not recruiting
NCT03087019 Phase II Pembrolizumab Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Active, not recruiting
NCT02818920 Phase II Pembrolizumab Neoadjuvant Pembrolizumab Active, not recruiting
NCT03457948 Phase II Pembrolizumab Pembrolizumab + Yttrium-90 Pembrolizumab and Liver-Directed Therapy in Treating Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases Recruiting
NCT03661723 Phase II Bevacizumab Pembrolizumab Bevacizumab + Pembrolizumab Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Recruiting
NCT03311308 Phase I Metformin + Pembrolizumab Pembrolizumab A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma Recruiting
NCT02575404 Phase I GR-MD-02 Pembrolizumab GR-MD-02 Plus Pembrolizumab in Melanoma Patients Recruiting
NCT03284424 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629) Recruiting
NCT02411656 Phase II Pembrolizumab MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC) Recruiting
NCT02305186 Phase Ib/II Pembrolizumab Capecitabine Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer Recruiting
NCT03136055 Phase II Irinotecan + Pembrolizumab Paclitaxel + Pembrolizumab Pembrolizumab Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas Recruiting
NCT02998268 Phase II Pembrolizumab Carboplatin + Paclitaxel Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma Recruiting
NCT02434354 Phase I Pembrolizumab A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma Recruiting
NCT02784171 Phase II Cisplatin + Pemetrexed Pembrolizumab Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Recruiting
NCT03574220 Phase I Pembrolizumab Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer Recruiting
NCT03395847 Phase I Pembrolizumab + Ramucirumab Pembrolizumab A Study of Pembrolizumab Monotherapy or in Combination With Other Agents in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma Active, not recruiting
NCT03428802 Phase II Pembrolizumab Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability Recruiting
NCT03783078 Phase III Pembrolizumab Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) Recruiting
NCT02768792 Phase II Pembrolizumab High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML Recruiting
NCT03582475 Phase I Etoposide Carboplatin + Docetaxel + Etoposide + Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate Recruiting
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02752074 Phase III Epacadostat + Pembrolizumab Pembrolizumab A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma Active, not recruiting
NCT03277638 Phase Ib/II Pembrolizumab Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma Recruiting
NCT02621021 Phase II Pembrolizumab Cyclophosphamide Fludarabine Aldesleukin A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab Recruiting
NCT02256436 Phase III Pembrolizumab A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) Active, not recruiting
NCT03341143 Phase II Pembrolizumab Fecal Microbiota Transplant (FMT) in Melanoma Patients Recruiting
NCT02337686 Phase II Pembrolizumab Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma Active, not recruiting
NCT03712605 Phase III Pembrolizumab Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer Recruiting
NCT03515629 Phase III Cemiplimab + Ipilimumab Pembrolizumab REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Active, not recruiting
NCT02337491 Phase II Pembrolizumab Bevacizumab + Pembrolizumab Pembrolizumab +/- Bevacizumab for Recurrent GBM Completed
NCT02939651 Phase II Pembrolizumab A Study of Pembrolizumab in Patients With Neuroendocrine Tumors Recruiting
NCT02609503 Phase II Pembrolizumab Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin Active, not recruiting
NCT03004183 Phase II Pembrolizumab AdV-tk + Valacyclovir SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC Recruiting
NCT02437071 Phase II Pembrolizumab Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients Active, not recruiting
NCT02362048 Phase II Acalabrutinib Pembrolizumab ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer Active, not recruiting
NCT03179917 Phase II Pembrolizumab Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma Recruiting
NCT02730546 Phase Ib/II Carboplatin + Paclitaxel Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery Suspended
NCT02963090 Phase II Pembrolizumab + Topotecan Pembrolizumab Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer Active, not recruiting
NCT03586024 Phase Ib/II Pembrolizumab Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL) Recruiting
NCT03233724 Phase Ib/II Pembrolizumab The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer Recruiting
NCT02581982 Phase II Pembrolizumab Paclitaxel Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer Recruiting
NCT02635360 Phase II Cisplatin Pembrolizumab Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer Recruiting
NCT02708641 Phase II Pembrolizumab A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients 60 With AML Recruiting
NCT03274661 Phase II Pembrolizumab Pembrolizumab Activity in Patients With HR Competent and Deficient Tumors Recruiting
NCT03815058 Phase II Pembrolizumab + RO7198457 Pembrolizumab A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma. Recruiting
NCT02769520 Phase II Pembrolizumab Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck Recruiting
NCT03036488 Phase III Cyclophosphamide + Epirubicin Cyclophosphamide + Doxorubicin Pembrolizumab Carboplatin + Paclitaxel Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Active, not recruiting
NCT03757689 Phase II Pembrolizumab Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma Recruiting
NCT02710396 Phase II Carboplatin + Pembrolizumab + Pemetrexed Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Genetic Predictors of Benefit to Pembrolizumab Recruiting
NCT02375672 Phase II Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer Active, not recruiting
NCT03901378 Phase II Carboplatin + Etoposide + Pembrolizumab Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma Not yet recruiting
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting
NCT01993719 Phase II Pembrolizumab Aldesleukin Fludarabine Cyclophosphamide Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma Recruiting
NCT02721732 Phase II Pembrolizumab Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting
NCT02581943 Phase II Paclitaxel Pembrolizumab Carboplatin Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer Recruiting
NCT02054806 Phase I Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) Active, not recruiting
NCT03632941 Phase II Pembrolizumab AVX901 + Pembrolizumab AVX901 A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer Recruiting
NCT02658019 Phase II Pembrolizumab Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma Active, not recruiting
NCT02520154 Phase II Carboplatin + Paclitaxel Pembrolizumab Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer Recruiting
NCT02919969 Phase II Pembrolizumab Pembrolizumab in Refractory Metastatic Anal Cancer Recruiting
NCT02674061 Phase II Pembrolizumab Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) Active, not recruiting
NCT03553836 Phase III Pembrolizumab Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) Recruiting
NCT02702414 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) Active, not recruiting
NCT02499952 Phase II Pembrolizumab Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors Terminated
NCT03225664 Phase Ib/II Pembrolizumab Pembrolizumab + Trametinib BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT02620423 Phase I Gemcitabine Fluorouracil Irinotecan Reolysin Leucovorin Pembrolizumab Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma Completed
NCT03735290 Phase Ib/II Pembrolizumab Intuvax + Pembrolizumab A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) Recruiting
NCT03374488 Phase III Epacadostat + Pembrolizumab Pembrolizumab Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma Active, not recruiting
NCT02673333 Phase II Pembrolizumab Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Active, not recruiting
NCT02940496 Phase Ib/II Pembrolizumab Pembrolizumab (MK-3475) in Hepatocellular Carcinoma Active, not recruiting
NCT03057613 Phase II Pembrolizumab A Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck Recruiting
NCT02359565 Phase I Pembrolizumab Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas Recruiting
NCT03727880 Phase II Defactinib + Pembrolizumab Pembrolizumab Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma Recruiting
NCT02365766 Phase Ib/II Cisplatin Pembrolizumab Gemcitabine Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer Recruiting
NCT03291353 Phase 0 Pembrolizumab Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia Withdrawn
NCT03361865 Phase III Epacadostat + Pembrolizumab Pembrolizumab Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) Active, not recruiting
NCT03383094 Phase II Pembrolizumab Cisplatin + Radiotherapy Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer Recruiting
NCT03631706 Phase II M7824 Pembrolizumab M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT02852655 Phase 0 Pembrolizumab A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma Active, not recruiting
NCT02332980 Phase II Pembrolizumab A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma Recruiting
NCT02879994 Phase II Pembrolizumab Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer Active, not recruiting
NCT02892201 Phase II Pembrolizumab Pembrolizumab in HNSCC With Residual Disease After Radiation Recruiting
NCT03166254 Phase I Pembrolizumab Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer Withdrawn
NCT03085719 Phase II Pembrolizumab Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN Recruiting
NCT02343952 Phase II Pembrolizumab Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC Active, not recruiting
NCT03322540 Phase III Pembrolizumab Epacadostat + Pembrolizumab Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer Active, not recruiting
NCT02339324 Phase I Interferon alpha-2b Pembrolizumab Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b Active, not recruiting
NCT02954874 Phase III Pembrolizumab Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting
NCT03867084 Phase III Pembrolizumab Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) Recruiting
NCT02535247 Phase II Pembrolizumab Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma Active, not recruiting
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Recruiting
NCT02987166 Phase I Pembrolizumab HDCRT Plus Pembrolizumab in Advanced Malignancies (UVA-AM-001) Active, not recruiting
NCT02858869 Phase 0 Pembrolizumab Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Recruiting
NCT03382899 Phase II Pegilodecakin + Pembrolizumab Pembrolizumab Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 1)mall Cell Lung Cancer (Cypress 1) Recruiting
NCT02693535 Phase II Cobimetinib + Vemurafenib Regorafenib Pembrolizumab Temsirolimus Dasatinib Pertuzumab + Trastuzumab Ipilimumab + Nivolumab Crizotinib Palbociclib Sunitinib Olaparib Cetuximab TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Recruiting
NCT02500121 Phase II Pembrolizumab Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer Active, not recruiting
NCT02324582 Phase I Pembrolizumab MK-3475/BCG in High Risk Superficial Bladder Cancer Recruiting
NCT02537444 Phase II Acalabrutinib Pembrolizumab ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191) Unknown status
NCT02730130 Phase II Pembrolizumab Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients Active, not recruiting
NCT03407170 Phase II Pembrolizumab Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) Active, not recruiting
NCT03279692 Phase II Pembrolizumab Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Recruiting
NCT03391973 Phase II Pembrolizumab Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP) Recruiting
NCT02702401 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Active, not recruiting
NCT02981914 Phase 0 Pembrolizumab Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation Recruiting
NCT02775851 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery Recruiting
NCT03197506 Phase II Pembrolizumab + Temozolomide Pembrolizumab Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma Suspended
NCT02252042 Phase III Pembrolizumab Methotrexate Cetuximab Docetaxel Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) Active, not recruiting
NCT03486197 Phase II Pembrolizumab Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma Recruiting
NCT03217071 Phase II Pembrolizumab Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer Recruiting
NCT02325557 Phase Ib/II Pembrolizumab ADXS31-142 ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046 Active, not recruiting
NCT03406858 Phase II Pembrolizumab Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer Recruiting
NCT02444741 Phase Ib/II Pembrolizumab MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03504163 Phase II Pembrolizumab Pembrolizumab (MK-3475) as First-line Therapy for Carcinoma in Situ (Tis) Non-Muscle-Invasive Bladder Cancer Recruiting
NCT03727061 Phase II Cisplatin + Fluorouracil Carboplatin + Fluorouracil Pembrolizumab Cetuximab Nivolumab Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer Recruiting
NCT03829332 Phase III Pembrolizumab Lenvatinib + Pembrolizumab Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naive Non-small Cell Lung Cancer (NSCLC)(MK-7902-007/E7080-G000-314/LEAP-007) Recruiting
NCT03307759 Phase I Pembrolizumab Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma (SABRseq) Recruiting
NCT02740920 Phase II Pembrolizumab Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker Active, not recruiting
NCT03295227 Phase I Pembrolizumab Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma Recruiting
NCT03425643 Phase III Cisplatin + Pemetrexed Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Cisplatin + Gemcitabine Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Recruiting
NCT03396471 Phase II Pembrolizumab Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary Recruiting
NCT02382406 Phase Ib/II Pembrolizumab Carboplatin + Nab-paclitaxel Carboplatin/Nab-Paclitaxel and MK-3475 in NSCLC Active, not recruiting
NCT03287050 Phase I Pembrolizumab Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma Recruiting
NCT03304639 Phase II Pembrolizumab Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer Recruiting
NCT02316002 Phase II Pembrolizumab Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer Active, not recruiting
NCT03347617 Phase II Pembrolizumab Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma Recruiting
NCT03259867 Phase II Nivolumab Pembrolizumab Combination of TATE and PD-1 Inhibitor in Liver Cancer Recruiting
NCT02301039 Phase II Pembrolizumab A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Active, not recruiting
NCT03878524 Phase I Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) Not yet recruiting
NCT02872025 Phase I Pembrolizumab Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS) Recruiting
NCT02407171 Phase Ib/II Pembrolizumab Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC Recruiting
NCT02971748 Phase II Pembrolizumab A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy Recruiting
NCT03126630 Phase Ib/II Pembrolizumab Anetumab ravtansine + Pembrolizumab Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma Recruiting
NCT02448303 Phase II Acalabrutinib Pembrolizumab Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer Completed
NCT03267888 Phase I Pembrolizumab Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma Recruiting
NCT03255018 Phase II Pembrolizumab Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas Recruiting
NCT03338959 Phase Ib/II Pembrolizumab Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma Suspended
NCT02440425 Phase II Paclitaxel Pembrolizumab Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer Active, not recruiting
NCT01953692 Phase I Pembrolizumab A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) Active, not recruiting
NCT03091478 Phase II Pembrolizumab Pembrolizumab in Patients With Leptomeningeal Disease Recruiting
NCT02335424 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52) Active, not recruiting
NCT02331251 Phase Ib/II Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) Terminated
NCT02603887 Phase I Pembrolizumab Pembrolizumab for Smoldering Multiple Myeloma (SMM) Active, not recruiting
NCT02351739 Phase II Pembrolizumab Acalabrutinib Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer Active, not recruiting
NCT02576977 Phase III Pomalidomide Pembrolizumab Dexamethasone Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) Active, not recruiting
NCT02521870 Phase I Pembrolizumab SD-101 A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma Active, not recruiting
NCT02574533 Phase I Pembrolizumab FANG vaccine Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma Completed
NCT03620019 Phase II Denosumab + Pembrolizumab Pembrolizumab Denosumab + Pembrolizumab in Patients With Stage IV Melanoma Recruiting
NCT02591615 Phase II Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pemetrexed Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC Recruiting
NCT03302234 Phase III Pembrolizumab Ipilimumab + Pembrolizumab Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598) Recruiting
NCT02493361 Phase II Pembrolizumab IL-12 gene Trial of pIL-12/MK-3475 in Metastatic Melanoma Active, not recruiting
NCT02085070 Phase II Pembrolizumab MK-3475 in Melanoma and NSCLC Patients With Brain Metastases Active, not recruiting
NCT02591654 Phase I Pembrolizumab MRI/PET Imaging to Assess Response to Pembrolizumab in Metastatic Melanoma Active, not recruiting
NCT02899793 Phase II Pembrolizumab Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer Recruiting
NCT03316872 Phase II Pembrolizumab Study of Pembrolizumab and Radiotherapy in Liver Cancer Recruiting
NCT03516708 Phase Ib/II Pembrolizumab Epacadostat Capecitabine + Oxaliplatin Epacadostat (INCB024360) and Pembrolizumab Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer Not yet recruiting
NCT01876511 Phase II Pembrolizumab Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors Recruiting
NCT02506153 Phase III Interferon alpha-2b Pembrolizumab High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Active, not recruiting
NCT01822652 Phase I Cyclophosphamide Fludarabine Pembrolizumab 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN Active, not recruiting
NCT03309878 Phase Ib/II Pembrolizumab Mogamulizumab + Pembrolizumab Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Lymphomas Recruiting
NCT02579863 Phase III Pembrolizumab Dexamethasone Lenalidomide Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) Active, not recruiting
NCT02971956 Phase II Pembrolizumab A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer Active, not recruiting
NCT02212730 Phase I Pembrolizumab A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) Active, not recruiting
NCT03025035 Phase II Pembrolizumab Pembrolizumab in Advanced BRCA-mutated Breast Cancer Recruiting
NCT03273153 Phase III Pembrolizumab Atezolizumab + Cobimetinib A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma Recruiting
NCT02819518 Phase III Paclitaxel Pembrolizumab Nab-paclitaxel Carboplatin + Gemcitabine Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) Active, not recruiting
NCT02775435 Phase III Carboplatin + Nab-paclitaxel Pembrolizumab Carboplatin + Paclitaxel A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) Active, not recruiting
NCT03891979 FDA approved Ciprofloxacin Metronidazole Pembrolizumab Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Not yet recruiting
NCT02707666 Phase I Pembrolizumab Cisplatin + Pemetrexed A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma Recruiting
NCT03486873 Phase III Pembrolizumab Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Recruiting
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting
NCT02268825 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers Terminated
NCT02555657 Phase III Pembrolizumab Eribulin Gemcitabine Vinorelbine Capecitabine Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) Active, not recruiting
NCT03051672 Phase II Pembrolizumab Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC Active, not recruiting
NCT02684461 Phase II Pembrolizumab Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel Recruiting
NCT02564263 Phase III Pembrolizumab Docetaxel + Irinotecan + Paclitaxel Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Active, not recruiting
NCT02688608 Phase II Pembrolizumab Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Recruiting
NCT02999477 Phase I Pembrolizumab Nab-paclitaxel A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer Recruiting
NCT02220894 Phase III Pemetrexed Carboplatin + Paclitaxel Pembrolizumab Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) Active, not recruiting
NCT02841748 Phase II Pembrolizumab A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study Recruiting
NCT02306850 Phase II Pembrolizumab Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma Completed
NCT02641093 Phase II Cisplatin Pembrolizumab Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma Recruiting
NCT02678572 Phase III Dacarbazine Ipilimumab Melphalan Pembrolizumab Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma Recruiting